Massimo Fabiani | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Human neuroinvasive Toscana virus infections in Italy from 2016 to 2023. Increased incidence in 2022 and 2023	EUROSURVEILLANCE	2025
Socioeconomic Inequalities in SARS-CoV-2 Infection and COVID-19 Health Outcomes in Urban Italy During the COVID-19 Vaccine Rollout, January–November 2021	JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE	2024
Correction to: Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy	JN. JOURNAL OF NEPHROLOGY	2024
Impatto del COVID-19 dopo l’inizio della vaccinazione in gruppi di popolazione a rischio, tra cui gli immunocompromessi: Italia 2021-2023	BOLLETTINO EPIDEMIOLOGICO NAZIONALE	2024
Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021	BMC PUBLIC HEALTH	2024
Effectiveness against severe COVID-19 of a seasonal booster dose of bivalent (original/Omicron BA.4-5) mRNA vaccines in persons aged ≥60 years: Estimates over calendar time and by time since administration during prevalent circulation of different Omicron subvariants, Italy, 2022–2023	VACCINE	2024
Accesso alla vaccinazione COVID-19 in Italia nel periodo 2020-2023 da parte degli stranieri non residenti: opportunità, sfide e criticità	BOLLETTINO EPIDEMIOLOGICO NAZIONALE	2024
Increasing situational awareness through nowcasting of the reproduction number	FRONTIERS IN PUBLIC HEALTH	2024
Impact of the 2023/24 autumn-winter COVID-19 seasonal booster campaign in preventing severe COVID-19 cases in Italy (October 2023–March 2024)	VACCINE	2024
Case-time series study on the short-term impact of meteorological factors on West Nile Virus incidence in Italy at the local-administrative unit level, 2012 to 2021	ENVIRONMENTAL RESEARCH	2024
Sex differences in response to COVID-19 mRNA vaccines in Italian population	EPIDEMIOLOGY AND INFECTION	2024
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study	THE LANCET INFECTIOUS DISEASES	2023
Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023	EUROSURVEILLANCE	2023
Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy. A retrospective matched cohort study	VACCINE	2023
Estimated effectiveness of a primary cycle of protein recombinant vaccine nvx-cov2373 against covid-19	JAMA NETWORK OPEN	2023
Lack of evidence of Chikungunya virus infection among blood donors during the Chikungunya outbreak in Lazio Region, Italy, 2017	VIRUSES	2022
Impatto della vaccinazione e della pregressa diagnosi sul rischio di infezione e di malattia severa associata a SARS-CoV-2: un’analisi dei casi diagnosticati nel mese di ottobre 2022	Impatto della vaccinazione e della pregressa diagnosi sul rischio di infezione e di malattia severa associata a SARS-CoV-2: un’analisi dei casi diagnosticati nel mese di ottobre 2022. Nota tecnica.	2022
Risk and protective factors for {SARS}-{CoV}-2 reinfections, surveillance data, Italy, August 2021 to March 2022	EUROSURVEILLANCE	2022
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022	THE LANCET	2022
Microbial Environmental Pollution in ICUs. Results, Trends, and Suggestions from a Long-Lasting Surveillance	ATMOSPHERE	2021